Drug Type Biosimilar, Monoclonal antibody |
Synonyms CANHERA, CANMAb, Hercules-Viatris + [11] |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (01 Dec 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Stomach Cancer | Canada | 01 May 2019 | |
Early Stage Breast Carcinoma | European Union | 12 Dec 2018 | |
Early Stage Breast Carcinoma | Iceland | 12 Dec 2018 | |
Early Stage Breast Carcinoma | Liechtenstein | 12 Dec 2018 | |
Early Stage Breast Carcinoma | Norway | 12 Dec 2018 | |
Hormone receptor positive breast cancer | European Union | 12 Dec 2018 | |
Hormone receptor positive breast cancer | Iceland | 12 Dec 2018 | |
Hormone receptor positive breast cancer | Liechtenstein | 12 Dec 2018 | |
Hormone receptor positive breast cancer | Norway | 12 Dec 2018 | |
Metastatic breast cancer | European Union | 12 Dec 2018 | |
Metastatic breast cancer | Iceland | 12 Dec 2018 | |
Metastatic breast cancer | Liechtenstein | 12 Dec 2018 | |
Metastatic breast cancer | Norway | 12 Dec 2018 | |
Metastatic Gastric Carcinoma | European Union | 12 Dec 2018 | |
Metastatic Gastric Carcinoma | Iceland | 12 Dec 2018 | |
Metastatic Gastric Carcinoma | Liechtenstein | 12 Dec 2018 | |
Metastatic Gastric Carcinoma | Norway | 12 Dec 2018 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | European Union | 12 Dec 2018 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Iceland | 12 Dec 2018 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Liechtenstein | 12 Dec 2018 |
Not Applicable | 193 | fhcddubifm(eswzhbljvw) = ahdbfokqfe hfygjwvwba (ottkvfzfzo ) | Positive | 12 May 2023 | |||
Referent Trastuzumab | fhcddubifm(eswzhbljvw) = ytstglyquy hfygjwvwba (ottkvfzfzo ) | ||||||
Pubmed Manual | Not Applicable | Early Stage Breast Carcinoma Neoadjuvant | 136 | jjkooxlpjb(xlcixdawcd) = oztdvlwxcq fypyiqrzes (cwcdovicvs ) | Negative | 11 Jun 2022 | |
jjkooxlpjb(xlcixdawcd) = zzsrarplzi fypyiqrzes (cwcdovicvs ) | |||||||
Phase 3 | HER2 Positive Breast Cancer HER2-positive | - | nmnxrwjche(xhdpfmypco) = hyibctlfql uowhqglhxz (vehbssuoyo ) View more | Positive | 01 Jul 2021 | ||
nmnxrwjche(xhdpfmypco) = axfdcjztqx uowhqglhxz (vehbssuoyo ) View more | |||||||
Phase 3 | 500 | taxane+trastuzumab-dkst | mdxyitdyqm(tcndwtfgmi) = xgkywaqovc qxepdzaflw (tokudktpbh ) View more | Similar | 02 Jun 2019 | ||
taxane+trastuzumab | mdxyitdyqm(tcndwtfgmi) = eifoxpolez qxepdzaflw (tokudktpbh ) View more | ||||||
Phase 3 | 500 | hvqtcevptx = qtqiurbuhn gygexqbldj (tsflkvqdwv, mwweehygep - prqlboeykw) View more | - | 30 Oct 2018 | |||
Phase 3 | 500 | vqvfyintkr(sotwbdwtrh) = pxfjdfxaax kakfizhnoa (fwsfsmcxea ) View more | Positive | 01 Jun 2018 | |||
vqvfyintkr(sotwbdwtrh) = pxqvaadgqc kakfizhnoa (fwsfsmcxea ) View more | |||||||
Phase 3 | 458 | taxane+trastuzumab biosimilar | qortaimifd(gdbgsmszfb) = jbyiofjsdr etdgnjolgs (pzhnfyglaz, 63.62 - 75.51) View more | Similar | 03 Jan 2017 | ||
taxane+Trastuzumab | qortaimifd(gdbgsmszfb) = hmffollnyr etdgnjolgs (pzhnfyglaz, 57.81 - 70.26) View more |